<DOC>
	<DOCNO>NCT00907478</DOCNO>
	<brief_summary>The purpose study evaluate change bone marrow morphology ( structure ) long-term exposure romiplostim .</brief_summary>
	<brief_title>Study Bone Marrow Morphology Adults Receiving Romiplostim Treatment Thrombocytopenia Associated With Immune Thrombocytopenia Purpura ( ITP )</brief_title>
	<detailed_description>Participants diagnose ITP accord American Society Hematology ( ASH ) Guidelines sequentially enrol follow group : - Bone marrow biopsy Baseline Year 1 - Bone marrow biopsy Baseline Year 2 - Bone marrow biopsy Baseline Year 3 . All participant receive romiplostim 3 year , unless withdrawn study early . Participants return one visit End Study ( EOS ) procedures 4 week romiplostim discontinuation , , participant withdraw study due presence collagen fibrosis , change grade 3 reticulin , 12 week discontinuation romiplostim .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Diagnosis ITP accord American Society Hematology ( ASH ) guideline Subject must bone marrow biopsy within one year prior plan first dose romiplostim ( available bone marrow tissue block unstained histological slide send central laboratory interpretation ) must consent pretreatment bone marrow biopsy within 3 week prior plan first dose romiplostim . Central laboratory interpretation require prior first dose romiplostim Subject must agree schedule bone marrow biopsy Year 1 , Year 2 , Year 3 follow romiplostim treatment unscheduled biopsy clinically indicate Subject â‰¥18 year age Baseline bone marrow reticulin grade 0 , 1 , 2 , 3 accord modify Bauermeister grade scheme assessed central laboratory interpretation Platelet count &lt; 50 x 10^9/L Must receive least 1 prior ITP therapy ( example ITP therapy include corticosteroid , intravenous immunoglobulin [ IVIG ] , splenectomy ) Subject ( legallyacceptable representative ) willing able provide write informed consent Baseline bone marrow biopsy positive collagen fibrosis Any known history currently active bone marrow stem cell disorder , hematological malignancy , myeloproliferative disorder , myelodysplastic syndrome Any current active malignancy Any prior exposure cytostatic chemotherapy radiotherapy malignancy Subject undergone pacemaker placement , cardiac ablation arrhythmia , and/or current treatment Vaughan Williams Class IA IC Class III agent ( Vaughan Williams , 1970 ) Subject participate study evaluate pegylated recombinant human megakaryocyte growth development factor ( PEGrHuMGDF ) , recombinant human thrombopoietin ( rHuTPO ) , thrombopoietin receptor agonist ( ie romiplostim eltrombopag ) Subject know hypersensitivity recombinant E coliderived product Subject currently enrol yet complete ( least 4 week since end ) investigational device drug trial ( ) subject receive investigational agent ( ) Other investigational procedure exclude Subject childbearing potential evidently pregnant ( eg positive pregnancy test ) breast feed Subject use adequate contraceptive precaution Subject kind disorder compromise ability subject give write informed consent legally acceptable representative and/or unable comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Idiopathic Thrombocytopenic Purpura</keyword>
	<keyword>Idiopathic Thrombocytopenia Purpura</keyword>
	<keyword>Immune Thrombocytopenic Purpura</keyword>
	<keyword>Immune Thrombocytopenia</keyword>
	<keyword>ITP</keyword>
</DOC>